

ACTEMBA 162MC/O OML CYDINCE

Texas Standard Prior Authorization Form Addendum

ACTEMBA ACTOEN 162 MC/O O MI

Molina Healthcare of Texas

Cytokine and CAM Antagonists – Actemra (Tocilizumab) (Medicaid)

This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information, sign, and date. Fax signed forms to Molina Pharmacy Prior Authorization Department at 1-888-487-9251. Please contact Molina Pharmacy Prior Authorization Department at 1-855-322-4080 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Actemra (Medicaid).

Drug Name (select from list of drugs shown / provide drug information)

ACTEMIKA 102MG/0.3ME 31KINGE		ACILIMRA ACIFLIN 102	ACTEMINA ACTIFEN 102 Mg/0.9 ME		
	Patie	nt Information			
Patient Name:					
Patient ID:					
Patient DOB:					
	Prescr	ribing Physician			
Physician Name:					
Physician Phone:					
Physician Fax:					
Physician Address:					
City, State, Zip:					
Diamasia		ICD Code:			
Diagnosis: Directions for admin	••	ICD Code:			
	relevant clinical notes, lab work, a	medication history and any other applica	ıble documentatio	o n.	
1. Is the requested drug required per court order? (court order required) If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 2.			Y	N	
2. Is the patient greater than or equal to 18 years of age? If the answer to this question is yes, go to question 3. If the answer to this question is no, go to question 7.			Y	N	
3. Does the patient have a diagnosis of rheumatoid arthritis (RA) in the last 730 days? If the answer to this question is yes, go to question 5. If the answer to this question is no, go to question 4.			Y	N	
4. Does the patient have a diagnosis of giant cell arteritis (GCA) in the last 730 days? If the answer to this question is yes, go to question 9. If the answer to this question is no, go to question 7.			Y	N	

5.	Does the patient have 1 claim for a DMARD in the last 180 days?	Y	N
	<u>DMARDs</u>		
	ARAVA		
	AZATHIOPRINE		
	AZULFIDINE		
	AZULFIDINE ENTAB		
	CYCLOSPORINE		
	CYCLOSPORINE MODIFIED		
	GENGRAF		
	HYDROXYCHLOROQUINE		
	IMURAN		
	LEFLUNOMIDE		
	METHOTREXATE		
	NEORAL		
	OTREXUP		
	PLAQUENIL		
	SANDIMMUNE		
	SULFASALAZINE		
	TREXALL		
	XATMEP		
	AMINE		
	If the answer to this question is yes, go to question 9.		
	If the answer to this question is no, go to question 6.		
6.	Is the request for continuation of therapy?	Y	N
	If the answer to this question is yes, go to question 9.		
	If the answer to this question is no, denied.		
7.	Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) or	Y	N
	systemic juvenile idiopathic arthritis (SJIA) in the last 730 days?		
	If the answer to this question is yes, go to question 8.		
	If the answer to this question is no, denied.		
0	Is the noticest constant have an equal to 2 years of each	Y	N.T
8.	Is the patient greater than or equal to 2 years of age? If the answer to this question is yes, so to question 0	I	N
	If the answer to this question is yes, go to question 9. If the answer to this question is no, denied.		
	if the diswer to this question is no, deficed.		
9.	Does the patient have a serious active infection (including Hepatitis B virus and/or tuberculosis)	Y	N
	in the last 180 days?		
	If the answer to this question is yes, denied.		
	If the answer to this question is no, go to question 10.		
10.	Is the request for a non-preferred drug?	Y	N
	If the answer to this question is yes, go to question 11.		
	If the answer to this question is no, approved for 365 days.		
11.	Has the patient failed a 30-day treatment with at least 1 preferred agent within the last 180 days?	Y	N
	If the answer to this question is yes, approved for 365 days.		
	If the answer to this question is no, go to question 12.		
10	To the second of all second se	37	NT
12.	Is there a documented allergy or contraindication to preferred agents in this class?	Y	N
	If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 13.		
	if the answer to this question is no, go to question 13.		
13.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?	Y	N
15.	If the answer to this question is yes, approved for 365 days.	1	14
	-, to this question is yes, approved for each ways.		

If the answer to this question is no, denied.					
Comments:					
I affirm that the information given on this form is true and accurate as of this date.					
Prescriber (or Authorized) Signature	Date				